Evaluating In House HSV PCR Capabilities, A Cost Benefit Analysis

Abstract

Neonatal HSV occurs in approximately 1 out of 3,200 to 10,000 live births, with 1500 cases reported annually and accounting for 0.2% of neonatal hospitalizations and 0.6% of In-hospital neonatal deaths in the US. HSV disease carries not only significant medical and financial costs, but considerable diagnostic challenges. The advent of the HSV PCR modality offers alleviation to the associated costs and diagnostic dilemma. Previous studies have cited relative decrease in median lab turnaround time when implementing real-time PCR capabilities, resulting In quantifiable decreased hospital LOS for pediatric patients and institutional lab cost savings. In addition, significant iatrogenic complications are associated with parenteral Acyclovir therapy including nausea and vomiting, hepatic and renal injury, and local inflammation to injection sites.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 30, 2016
Accession Number
AD1036174

Entities

People

  • Austin Baltensperger

Organizations

  • 59th Medical Wing

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Acquisition
  • Air Force
  • Cost Benefit Analysis
  • Costs
  • Department Of Defense
  • Digital Information
  • Education
  • Health Services
  • Hospitalizations
  • Hospitals
  • Intellectual Property
  • Law
  • Materials
  • Patient Care
  • Students
  • Therapy

Fields of Study

  • Medicine

Readers

  • Medical or Health Care Field.
  • Trauma or Military Medicine
  • Virology (or Medical Virology).